Myrexis (MYRX) Stock Price

Myrexis Price

OTC·CLOSED
0.00
​
Market closed

Revenue at Myrexis has contracted by 57.7% per year over the past 5 years to 185,000.00 USD. Myrexis's net margin stands at -20,923.2%, down from -785.6% several years earlier. Myrexis currently offers a dividend yield of about 0.36%.

Myrexis stock price

Access this data via the Eulerpool API

Myrexis business model & stock analysis

Myrexis, Inc. is in the process of evaluating strategic alternatives, including focusing on identifying, evaluating and making financial investments in life sciences assets. The company is headquartered in New York City, New York and currently employs 1 full-time employees. The company went IPO on 2009-06-12. The firm was a biopharmaceutical company that generated a pipeline of differentiated drug candidates in oncology and autoimmune diseases. In February 2012, it announced that the Company has suspended development activity on all of its preclinical and clinical programs and retained Stifel Nicolaus Weisel, an investment banking firm, to assist in reviewing and evaluating a full range of strategic alternatives to enhance shareholder value. The firm determines to pursue the acquisition of one or more commercial-stage biopharmaceutical assets, with the goal of building a commercial-stage biopharmaceutical company. The firm operates in pharmaceutical development and related research activities. The Company’s revenues were derived from research performed in the United States and, all of the Company’s long-lived assets are located in the United States.

Frequently asked questions about Myrexis

Converted at the current exchange rate, the Myrexis share trades at 0.00 EUR (0.00 USD).

The revenue cannot currently be calculated for Myrexis.

The profit cannot currently be calculated for Myrexis.

The P/E ratio cannot be calculated for Myrexis at the moment.

The P/S cannot be calculated for Myrexis currently.

The Eulerpool Quality Score for Myrexis is 2/10.

The ISIN of Myrexis is US62856H1077. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Myrexis is MYRX. The ticker symbol is used to trade Myrexis shares on the stock exchange.

Fair ValueTerminal
0.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website myrexis.com
Currency
USD
Initial public offering
Jun 12, 2009
ISIN
US62856H1077
Cusip
62856H107
Market capitalization
27,584.00 USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
0.02
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-999.23 %
Last updated Oct 8, 2026, 10:03 PM

Myrexis Peer Group

Myrexis Ticker

OTC · MYRXOTC · MYRX

Myrexis FIGI

MYRX:US · BBG000SGWJ97MYRX:PQ · BBG000SGWNK5MYRX:UV · BBG000SGWPB0

All fundamentals and in-depth analysis of Myrexis

Our stock analysis for Myrexis stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Myrexis. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.